Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: Variable relation to age, HbA1c, and insulin dose

Diabetes Care

Volumn 39, Issue 10, 2016, Pages 1664-1670

  Hao, Wei ^a   Gitelman, Steven ^b   Di Meglio, Linda A ^c   Boulware, David ^d   Greenbaum, Carla J ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; CHILD; CONTROLLED STUDY; DISEASE DURATION; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HISTORY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INTERVENTION STUDY; MIXED MEAL TOLERANCE TEST; ONSET AGE; PATIENT MONITORING; PROTEIN SECRETION; SURVIVAL TIME; TIME FACTOR; AGE; BLOOD; DIABETES MELLITUS, TYPE 1; DOSE RESPONSE; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; PANCREAS ISLET BETA CELL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; YOUNG ADULT;

EID: 84988934374     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0360     Document Type: Article

References (26)

1. Skyler JS, Greenbaum CJ, Lachin JM, et al. Type 1 Diabetes TrialNet Study Group. Type 1 Diabetes TrialNet-an international collaborative clinical trials network. Ann N Y Acad Sci 2008; 1150:14-24
2. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al.; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of betacell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971
3. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: Report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264
4. Mortensen HB, Hougaard P, Swift P, et al.; Hvidoere Study Group on Childhood Diabetes. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 2009;32:1384-1390
5. Sherry N, Hagopian W, Ludvigsson J, et al.; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protegé study): 1-year results from a randomised, placebocontrolled trial. Lancet 2011;378:487-497
6. Moran A, Bundy B, Becker DJ, et al.; Type 1 Diabetes Trial Net Canakinumab Study Group; AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013;381:1905-1915
7. Wherrett DK, Bundy B, Becker DJ, et al.; Type 1 Diabetes Trial Net GAD Study Group. Antigenbased therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial. Lancet 2011;378:319-327
8. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet 2011;378:412-419
9. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet MMF/DZB Study Group.Failure to preserve β-cell function with mycophenolate mofetil and daclizumab combined therapy in patientswith new-onset type 1 diabetes. Diabetes Care 2010;33:826-832
10. Pescovitz MD, Greenbaum CJ, Krause- Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti- CD20 Study Group.Rituximab, B-lymphocyte depletion, and preservation of β-cell function. N Engl J Med 2009;361:2143-2152
11. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769
12. Steffes MW, Sibley S, Jackson M, ThomasW. β-cell function and the development of diabetes- related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003;26: 832-836
13. Lachin JM, Mc Gee P, Palmer JP; DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014;63:739-748
14. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial: A randomized, controlled trial. Ann Intern Med 1998;128:517-523
15. Brooks AM, OramR, Home P, Steen N, Shaw JA. Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation. Diabetes Care 2015;38:105-112
16. Vantyghem MC, Raverdy V, Balavoine AS, et al. Continuous glucosemonitoring after islet transplantation in type 1 diabetes: An excellent graft function (b-score greater than 7) is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (b-score greater than 3). J Clin Endocrinol Metab 2012;97:E2078-E2083
17. Kessler L, Passemard R, Oberholzer J, et al.; GRAGIL Group. Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation: Interest of continuous glucose monitoring. Diabetes Care 2002;25:2256-2262
18. Greenbaum CJ, Beam CA, Boulware D, et al.; Type 1 Diabetes TrialNet Study Group.Fall in C-peptide during first 2 years from diagnosis: Evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012;61:2066-2073
19. Davis AK, DuBose SN, Haller MJ, et al.; T1D Exchange Clinic Network.Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 2015; 38:476-481
20. Zampeli E, Vlachoyiannopoulos PG, Tzioufas AG. Treatment of rheumatoid arthritis: Unraveling the conundrum. J Autoimmun 2015;65:1-18
21. Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986;2:119-124
22. Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 2015;125:3285-3296
23. Rigby MR, DiMeglio LA, Rendell MS, et al.; T1DAL Study Team.Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2013;1:284-294
24. Herold KC, Gitelman SE, Ehlers MR, et al.; AbATE Study Team.Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013;62:3766-3774
25. Pescovitz MD, Greenbaum CJ, Bundy B, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and β-cell function: Two-year results. Diabetes Care 2014;37:453-459
26. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group.Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: Followup 1 year after cessation of treatment. Diabetes Care 2014;37:1069-1075